Erata is a prescription anticonvulsant playing a role in managing diverse types of seizure disorders. Its use is relevant in clinical settings marked by increased discomfort or tension, focusing on symptomatic relief. It may be commonly used alone or in combination with other medications to manage various seizure types across all age groups, from infants to older adults.

The use of this medication is relevant for supporting patients across conditions characterized by periods of heightened symptoms, including partial-onset seizures, myoclonic seizures (like those in Juvenile Myoclonic Epilepsy), and primary generalized tonic-clonic seizures. It is applied across therapeutic domains where additional symptomatic support is needed, particularly in complex or refractory epilepsy. For patients facing motor events or episodic activity, Erata is applied in managing symptoms related to heightened physiological activity, which provides supportive relief by helping to support general well-being during symptomatic phases.

Quick Fact: Relief for Seizure Manifestations

Regulatory References

1. NIH MedlinePlus overview of Levetiracetam

Official Eligibility Profile for Erata (Levetiracetam)

Regulatory documents strictly define eligibility based on patient demographics, physiological status, and absolute contraindications.

Summary of Regulatory Restrictions

The medicine's eligibility is highly dependent on the patient's age and the integrity of their renal function, which is the primary route of elimination. Regulatory guidelines mandate individualized management for patients with organ impairment and explicitly define specific age thresholds that determine eligibility for its monotherapy versus adjunctive treatment roles.

Interactions with other medicines and products

Erata (Levetiracetam) is officially documented to have a low potential for many common drug-drug interactions. Regulatory information confirms the medicine is neither a substrate for, nor an inhibitor of, the major cytochrome P450 enzyme systems. Furthermore, Levetiracetam's low plasma protein binding (less than 10%) indicates that competitive transporter-mediated interactions are unlikely to be clinically significant.

The official interaction profile is structured around clearance alterations and additive effects:

• Pharmacokinetic Interactions: Co-administration with enzyme-inducing antiepileptic drugs (AEDs), such as Carbamazepine, results in an approximate 22% increase of apparent clearance of Levetiracetam. Conversely, Levetiracetam does not significantly affect the plasma concentrations of co-administered AEDs like Valproic acid, Topiramate, or Lamotrigine.

• Pharmacodynamic and Substance Interactions: Caution is advised when combining Erata with Central Nervous System (CNS) depressants, including alcohol, as co-administration can lead to additive effects, potentially intensifying nervous system effects like somnolence or dizziness. The extent of bioavailability is not affected by food, meaning there are no mandatory timing rules or separation requirements for administration relative to meals.

• Population-Specific Considerations: Official labeling notes that Levetiracetam's clearance is dependent on renal function. For patients with renal impairment, this reduced clearance necessitates consideration of the dosage due to the documented interaction with the body’s elimination pathway. The only formal contraindication is due to a documented hypersensitivity to Levetiracetam or other pyrrolidone derivatives.

Erata is thought to primarily target the synaptic vesicle protein 2A (SV2A), a glycoprotein embedded in the membrane of synaptic vesicles within the central nervous system. The drug acts as a modulator by binding reversibly and stereoselectively to this protein. This interaction is hypothesized to stabilize the SV2A conformation, thereby limiting the efficacy of presynaptic calcium-dependent vesicle release. The molecular consequence is a reduction in the release of excitatory neurotransmitters, such as glutamate, particularly during high-frequency neuronal firing. This intracellular modulation impedes the hypersynchronization of neuronal populations and the subsequent propagation of abnormal electrical discharges. Downstream cascades also involve a partial inhibition of N-type voltage-gated calcium channels and an opposition of negative modulation of GABA- and glycine-gated currents, which further contribute to limiting neuronal excitability. The system-level physiological consequence is the modulation of excessive neuronal activity within the central nervous system.

Erata (Levetiracetam) is administered through two primary routes: oral intake, utilizing immediate-release tablets, an oral solution, or extended-release tablets; and intravenous (IV) infusion. The IV route is designated for temporary use when oral administration is not practically feasible.

The standard adult dosing regimen is initiated at 500 mg taken twice daily (BID) for immediate-release forms. The total daily dose is then gradually increased, or titrated, by 1000 mg/day increments, typically over two-week intervals, toward a maximum daily dose of 3000 mg/day. The extended-release form is administered once daily (QD).

Administration is permissible with or without food. However, specific procedural constraints apply to the dosage forms: extended-release tablets must be swallowed whole and must not be cut, crushed, or chewed. The IV concentrate requires mandatory dilution in at least 100 mL of a compatible fluid and subsequent administration as a 15-minute infusion.

Dosing requires modification for specific patient populations. The regimen must be reduced and individualized in all patients with impaired renal function due to the drug's primary elimination pathway. For pediatric use, the dose is calculated based on body weight and administered twice daily. Treatment is typically long-term and must be gradually withdrawn by tapering the dose when discontinuation is required.

Erata: Overview of Studies

The clinical evaluation of Erata relies on randomized controlled trials (RCTs), comparative studies, and long-term observational follow-up studies. Research monitors changes in the frequency and type of seizures in different patient groups. Research describes group patterns observed in the studies and is not intended for individual predictions.

Clinical Evaluation of Core Indications

The research base for partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures primarily includes short-term, randomized, placebo-controlled trials. These studies focused on the medicine's role as an adjunctive therapy (add-on treatment) for conditions characterized by fluctuating or episodic manifestations. Research was conducted across adult, adolescent, and pediatric cohorts, often examining the proportion of patients who achieved a substantial reduction in seizure frequency (the responder rate). The evidence for adjunctive use in these core indications is generally categorized as High Level, reflecting consistent findings across the pivotal trials.

Long-Term Data and Research Gaps

Beyond initial trials, outcomes over extended treatment periods are assessed through open-label observational studies, which track treatment retention rates over periods of up to three years or more. The evidence level for these long-term outcomes is categorized as Moderate, as these studies lack the internal validity of controlled trials. Research gaps include the need for more extensive controlled data regarding the medicine’s use as a monotherapy (single treatment) and the absence of fully established long-term functional and cognitive outcomes, particularly in children. Limited data also remains for certain groups, such as controlled studies involving use during pregnancy.

Key Studies & References Efficacy and Tolerability of Intravenous Levetiracetam in Children (Focus on Pediatric Populations)

Common questions about Erata (FAQ)

Q: What is the main reason Erata is prescribed by doctors?

Official product information indicates that Erata is approved as a treatment for certain types of seizures. It is indicated as monotherapy (single treatment) or as an adjunctive (add-on) therapy for partial-onset seizures. The medicine is also indicated for myoclonic and primary generalized tonic-clonic seizures associated with certain forms of epilepsy.

Q: How quickly should I expect to feel any difference from taking Erata?

Studies show that the drug is rapidly absorbed into the body after an immediate-release oral dose, typically reaching its highest levels in the blood within about one hour. Consistent blood levels, known as steady-state concentrations, are generally achieved after about two days of consistent twice-daily dosing. This is based on regulatory information on the drug’s pharmacokinetics (how the body handles the drug).

Q: What happens if I forget to take Erata one day?

Instructions for managing a missed dose can vary depending on the specific product and treatment plan. Official guidance generally advises against taking a dose too late or doubling the dose to compensate for a missed one. Consulting a prescriber or the Patient Information Leaflet can provide guidance on managing a missed dose.

Q: Can Erata cause weight gain or weight loss?

Regulatory data from clinical trials generally suggest that the drug is considered weight-neutral for many patients. This means that the rate of reporting weight gain or weight loss was often similar to that seen in patients taking a placebo. However, instances of weight changes have been reported as adverse events in clinical trials.

Q: Does Erata affect sleep or cause drowsiness?

Yes, official product information lists somnolence (drowsiness) and fatigue as common adverse reactions. These nervous system effects were reported by both adult and pediatric patients during clinical trials.

Q: Is it common to have headaches when starting Erata?

Headache is listed among the very common adverse reactions noted in official regulatory documents. This means that headaches are categorized as a very common side effect reported in clinical trials.

Q: How long does Erata stay in your system after stopping it?

Official information on the drug's elimination, or pharmacokinetics, shows the plasma elimination half-life is approximately 6 to 8 hours in healthy adults. The drug is eliminated from the body primarily through the kidneys.

Q: Is Erata safe to take if I am already on a blood pressure medication?

The official drug profile indicates a low potential for general drug-drug interactions, partly because it is not significantly processed by major liver enzymes. While this is true, it is important to check the full FDA label for any specific, known interactions with blood pressure medications.

Q: Can taking Erata affect lab test results?

Official regulatory documents report that the medicine can sometimes affect lab test results. Changes have been noted, such as reductions in certain white blood cell counts (leukopenia) and decreased red blood cell counts (anemia).

Q: What are the most commonly reported side effects of Erata?

Very common side effects (occurring in 10% or more of patients) listed in official information include somnolence (drowsiness), dizziness, headache, and nasopharyngitis (common cold symptoms).

Q: Is Erata approved for use in children or adolescents?

Yes, the drug is officially approved for use in younger populations, but its use varies by age and seizure type. It is indicated as an add-on therapy for partial-onset seizures in children from 4 years of age, and in adolescents (from 12 years) for myoclonic and primary generalized tonic-clonic seizures.

Q: Can older adults (seniors) safely take Erata?

Official product information confirms the drug can be used in the older adult population. However, official documents note that dose adjustments may be necessary for older adults due to the potential for age-related decline in kidney function.

Q: Does Erata interact with common pain relievers like ibuprofen?

Formal regulatory interaction studies with common over-the-counter pain relievers, like NSAIDs such as ibuprofen, are generally not included in official documents. However, the regulatory profile states the drug has a low potential for general drug interactions.

Q: What is Erata considered an addictive medication?

Official regulatory authorities, such as the U.S. Drug Enforcement Administration (DEA), do not classify this medicine as a controlled substance. Therefore, it is not generally associated with potential for abuse or dependence.

Q: What should I know about the long-term use of Erata?

Treatment is often utilized as a long-term therapy for chronic conditions. Studies tracking long-term use suggest that most patients who continue treatment do not appear to develop tolerance to the drug's anti-seizure effects over time.

Q: What is the expected duration of treatment with Erata?

The official duration of treatment is typically long-term for the management of chronic conditions. If treatment is to be discontinued for any reason, official guidance requires it to always be done gradually by tapering the dose.

Q: What is the risk of having a serious side effect with Erata?

Regulatory warnings highlight the risk of serious behavioral changes and psychiatric symptoms, including suicidal ideation and hostility. Serious behavioral changes and dermatological reactions are highlighted as risks that warrant close observation.

Q: Can Erata cause stomach problems or nausea?

Yes, official product information lists nausea and vomiting as common adverse reactions, reported in 1% to 10% of patients in clinical trials.

Q: Is it possible to develop a tolerance to Erata over time?

Long-term follow-up studies suggest that the majority of patients who remain on treatment after the first year generally do not appear to develop tolerance to the antiepileptic effects with chronic exposure.

Q: Can Erata be taken with vitamins or herbal supplements?

Official documents indicate a low potential for drug interactions due to the drug’s metabolism. However, specific regulatory studies on every vitamin or herbal supplement are typically not available. It is recommended that prescribers be informed about all co-administered products.

Q: What types of patients should definitely NOT use Erata?

Official regulatory information states the drug is contraindicated (should not be used) if a patient has a known allergy (hypersensitivity) to the active substance, Levetiracetam, or to other pyrrolidone derivatives. This is the primary restriction noted in the official documents.

Q: Does Erata have a known effect on mood or anxiety?

Yes, official warnings note that the medicine may cause behavioral abnormalities and psychiatric symptoms. These can include feelings of anxiety, agitation, anger, depression, and, in rare instances, psychotic symptoms.

Q: Can I drive or operate machinery after taking Erata?

Regulatory documents advise patients to use caution when driving or operating machinery. This is because the medicine may cause central nervous system symptoms such as somnolence (drowsiness) and dizziness. The official recommendation is that patients do not drive or operate machinery until they have gained sufficient experience on the drug.

Q: What kind of research is currently being conducted on Erata?

Official research summaries indicate that there are still areas being investigated. These include the need for more controlled data regarding its use as a single treatment (monotherapy) and for long-term functional and cognitive outcomes, especially in children.

Q: Are there any official warnings associated with Erata?

Yes, official warnings and precautions are detailed in the product information. These include the potential for behavioral abnormalities and psychotic symptoms, the risk of suicidal ideation, and the occurrence of serious dermatological reactions.

Q: Can Erata interact with birth control pills?

Regulatory studies have confirmed that the drug does not significantly affect the blood concentrations of common ingredients in oral contraceptives, such as ethinylestradiol and levonorgestrel. Based on this interaction profile, the medicine does not typically interfere with birth control pills.

Q: What information is available about the effectiveness of Erata in different patient groups?

Official information confirms that effectiveness has been studied in different patient groups. These studies include data on the drug's use as an add-on therapy in adults, adolescents, and children for specific seizure types, such as partial-onset seizures.

Q: If I have a kidney condition, is Erata safe for me?

Official regulatory documents state that the drug can be used in patients with impaired renal function (a kidney condition). However, official documents indicate the dose typically requires reduction and individualization for these patients because the drug is primarily eliminated by the kidneys.

Q: Is it normal to feel tired during the first week of taking Erata?

Yes, somnolence (drowsiness) and fatigue are common side effects listed in official documents. The product information indicates that the incidence of some side effects, including drowsiness, tends to be more frequent when treatment is first initiated.

Q: Does Erata have potential side effects on the liver?

The official profile shows the drug is not significantly processed by the liver, and dosage adjustment is not typically needed for mild to moderate liver impairment. While rare, regulatory reports have included cases of clinically apparent drug-induced liver injury.

Q: What are the official clinical trials showing about Erata?

Pivotal trials reported in regulatory documents demonstrate the drug's efficacy as an add-on treatment. They show a significantly greater proportion of patients achieved a ge 50% reduction in seizure frequency when using the drug compared to placebo.

Q: What does the FDA label say about taking Erata?

The FDA label is the authoritative document providing official guidance on the medicine. It contains key information, including approved indications (uses), specific contraindications (who should not use it), and warnings about serious risks like suicidal ideation and behavioral changes.

Q: What are the restrictions on who can use Erata based on official documents?

The official restrictions are primarily the contraindication for patients with a known hypersensitivity (allergy) to the drug or other pyrrolidone derivatives. Additionally, official documents mandate that the dose must be adjusted for patients with impaired kidney function.

How to Store and Dispose of Erata (Levetiracetam)

Official regulatory guidelines define strict conditions for the storage and disposal of Erata to maintain its stability and ensure safety.

Mandatory Storage Conditions

Erata must be stored at controlled room temperature, typically below 25°C (77 F) or 30°C (86 F), and must be protected from both light and excess moisture. The medication must be kept in its original container and the cap must remain tightly closed.

Stability and Child Safety

The oral solution has a specific in-use stability limit of seven months after the bottle is opened. All forms of Erata must be stored out of the sight and reach of children and kept in a secure, locked-up location.

Disposal Instructions

Unused or expired Erata must not be flushed down the toilet or poured into any drain. The preferred disposal method is through an official drug take-back program. If a take-back program is unavailable, the medicine should be prepared for household trash disposal by mixing it with an unappealing substance, such as dirt or used coffee grounds, before sealing it in a bag.